DATROWAY Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to…
HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer’s Disease
HONG KONG, Oct. 2, 2025 /PRNewswire/ -- A landmark study conducted by…
Trianz Achieves AWS Premier Tier Status in the Amazon Web Services Partner Network
SANTA CLARA, Calif., Sept. 4, 2025 /PRNewswire/ -- Trianz, a digital transformation…
Hexaware Achieves AWS Premier Tier Status in the Amazon Web Services Partner Network
MUMBAI, India and ISELIN, N.J. Â , Sept. 2, 2025 /PRNewswire/ -- Hexaware…
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented…
Hyundai Motor Group Presents Hydrogen Vision for Energy Transition at CEM16
Hyundai Motor Group highlighted hydrogen’s role in decarbonization and energy resilience during…
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information…
The Third China International Supply Chain Expo Concludes in Beijing
Event Builds Momentum for Deeper International Supply Chain Cooperation BEIJING, July 22,…
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
June 21, 2025 18:00 ET Â | Source: BioAge Labs, Inc. Treatment with…
Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people…